Treatment of relapsed and refractory acute myelogenous leukemia
Treatment of relapsed and refractory acute myelogenous leukemia
复制标题
DOI：
10.1038/sj.leu.2401568
复制
发表时间：
2000-03-01
期刊：
影响因子：
11.4
通讯作者：
Estey, EH
中科院分区：
文献类型：
--
作者：
Estey, EH
有证据表明，复发性和难治性急性髓性白血病（AML）的挽救治疗应根据患者完全缓解（CR）的持续时间（结局的主要预测因素）而有所不同。虽然标准治疗方案产生的CR率高于研究治疗方案，但这些CR率并没有转化为初始缓解持续时间为
Evidence suggests that the salvage therapy utilized for relapsed and refractory acute myelogenous leukemia (AML) should differ based on the duration of a patient's complete remission (CR), the principal predictor of outcome. While standard regimens have produced higher CR rates than investigational regimens, these rates have not translated into improved survival in patients with initial remission durations of